Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. It is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.

Number of employees : 16 people.
Sales per Business
20202021Delta
Dermatological and Gastrointestinal Drugs0.33100%---
USD in Million
Sales per region
20202021Delta
North America0.33100%---
USD in Million
Managers
Name Title Age Since
Pardeep Nijhawan, Dr. Chief Executive Officer, Secretary & Director 50 2019
Michael Brooks, Dr. President 43 2019
Kathi Niffenegger Chief Financial Officer 64 2019
Blair Gordon, Dr. Vice President-Research & Development - 2016
Sean A. MacDonald Chairman 44 2017
Lorin K. Johnson, Dr. Independent Director 68 2019
Paul William Pay Independent Director 66 2019
Carlo Sistilli Independent Director 64 2019
Peter A. van der Velden Independent Director 59 2019
Gary Koppenjan Vice President-Investor Relations & Communications - 2016
Members of the board
Name Title Age Since
Sean A. MacDonald Chairman 44 2017
Pardeep Nijhawan, Dr. Chief Executive Officer, Secretary & Director 50 2019
Lorin K. Johnson, Dr. Independent Director 68 2019
Frank R. Oakes Director 70 2010
Paul William Pay Independent Director 66 2019
Carlo Sistilli Independent Director 64 2019
Peter A. van der Velden Independent Director 59 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 13,295,403 9,581,478 72.1% 0 0.0% 72.1%
Shareholders
NameEquities%
Pardeep Nijhawan 2,675,964 19.8%
Lumira Capital Investment Management, Inc. 2,072,879 15.3%
The Vanguard Group, Inc. 106,609 0.79%
Virtu Financial BD LLC 105,512 0.78%
Geode Capital Management LLC 77,249 0.57%
Renaissance Technologies LLC 74,100 0.55%
1919 Investment Counsel LLC 23,438 0.17%
Two Sigma Investments LP 22,491 0.17%
180 Wealth Advisors LLC 20,000 0.15%
Morgan Stanley & Co. LLC 17,333 0.13%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Edesa Biotech, Inc.
Sector Bio Therapeutic Drugs